TG Therapeutics Inc., of New York, reported updated results from its phase II study of TG-1101 (ublituximab), its glycoengineered anti-CD20 monoclonal antibody, in an oral presentation during the 13th International Congress on Malignant Lymphoma in Lugano, Switzerland.